HC Wainwright Issues Optimistic Outlook for ALLO Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Analysts at HC Wainwright increased their Q1 2025 EPS estimates for shares of Allogene Therapeutics in a research note issued on Wednesday, March 19th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.27) per share for the quarter, up from their prior estimate of ($0.29). HC Wainwright currently has a "Buy" rating and a $8.00 target price on the stock. The consensus estimate for Allogene Therapeutics' current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Allogene Therapeutics' Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.30) EPS and FY2025 earnings at ($1.14) EPS.

ALLO has been the subject of a number of other reports. Royal Bank of Canada reissued an "outperform" rating and set a $10.00 price objective on shares of Allogene Therapeutics in a report on Friday, March 14th. Canaccord Genuity Group reissued a "buy" rating and issued a $14.00 price objective on shares of Allogene Therapeutics in a research note on Friday, March 14th. Finally, Citizens Jmp upgraded Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 target price for the company in a research note on Friday, March 14th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $9.29.

Remove Ads

Allogene Therapeutics Trading Down 4.8 %

ALLO stock traded down $0.08 during trading on Friday, hitting $1.60. The company had a trading volume of 1,555,180 shares, compared to its average volume of 3,104,259. The company has a fifty day moving average price of $1.87 and a two-hundred day moving average price of $2.27. Allogene Therapeutics has a fifty-two week low of $1.32 and a fifty-two week high of $4.63. The company has a market cap of $347.62 million, a P/E ratio of -1.03 and a beta of 1.02.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.34) by $0.06.

Insider Buying and Selling

In other news, insider Timothy L. Moore sold 14,746 shares of the business's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $1.71, for a total transaction of $25,215.66. Following the completion of the transaction, the insider now directly owns 250,713 shares in the company, valued at approximately $428,719.23. The trade was a 5.55 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO David D. Chang sold 46,668 shares of the stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $1.96, for a total transaction of $91,469.28. Following the completion of the sale, the chief executive officer now owns 5,276,569 shares in the company, valued at $10,342,075.24. This represents a 0.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 104,866 shares of company stock valued at $194,461 over the last three months. Company insiders own 24.30% of the company's stock.

Hedge Funds Weigh In On Allogene Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company lifted its holdings in Allogene Therapeutics by 1.2% during the third quarter. The Manufacturers Life Insurance Company now owns 486,023 shares of the company's stock worth $1,361,000 after acquiring an additional 5,642 shares in the last quarter. California State Teachers Retirement System lifted its holdings in shares of Allogene Therapeutics by 6.0% during the 4th quarter. California State Teachers Retirement System now owns 135,554 shares of the company's stock valued at $289,000 after purchasing an additional 7,685 shares in the last quarter. Invesco Ltd. grew its position in shares of Allogene Therapeutics by 7.0% in the 4th quarter. Invesco Ltd. now owns 127,486 shares of the company's stock valued at $272,000 after purchasing an additional 8,359 shares during the period. ProShare Advisors LLC increased its stake in Allogene Therapeutics by 25.6% during the 4th quarter. ProShare Advisors LLC now owns 46,082 shares of the company's stock worth $98,000 after purchasing an additional 9,388 shares in the last quarter. Finally, Nordea Investment Management AB increased its stake in Allogene Therapeutics by 2.1% during the 4th quarter. Nordea Investment Management AB now owns 460,641 shares of the company's stock worth $986,000 after purchasing an additional 9,635 shares in the last quarter. Institutional investors and hedge funds own 83.63% of the company's stock.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).